Sharing drug checking results in a Canadian setting: a multi-site analysis.

BACKGROUND

Drug checking services (DCS) have been implemented as a harm reduction measure to address high rates of illicit drug morbidity and mortality. In addition to reducing individual-level risk, there is also potential for DCS users to increase community level awareness of drug market conditions through sharing of drug checking results. However, little is known about the patterns of information sharing among people who use DCS.

METHODS

Data were derived from a cross-sectional study conducted at 22 community harm reduction sites offering DCS across British Columbia (BC) between March 2021 and July 2024. Two variable selection methods - backwards stepwise selection and elastic net regularization - were used to fit models which explored the relationships between select socio-demographic characteristics, drug use patterns and experiences with drug checking with the main outcome measure: sharing drug checking results.

RESULTS

516 participants were included in the study (34 % women, median age 42); 274 (53 %) reported that they shared their drug checking results. Factors significantly and positively associated with sharing results in multivariable logistic regression analysis using both selection methods included: drug dealing, using DCS more than once, stable employment and white ethnicity. Among participants who reported they shared their drug checking results, 66 % reported sharing results with friends and family and 28 % reported sharing results with their drug dealer.

CONCLUSION

This study revealed that over half the study sample shared their drug checking results with others, with results sharing being positively associated with recent drug dealing, frequent DCS utilisation, employment and ethnicity. Drug checking results were most often shared with friends, family and drug dealers. These findings extend the evidence base of DCS as a harm reduction tool by demonstrating how engagement with DCS facilitates information dissemination amongst drug market actors.